# Optimization of G Protein-based RSV Vaccines

> **NIH NIH R43** · SCIOGEN, LLC · 2021 · $298,738

## Abstract

Abstract
The overall objective of this proposal is to develop G protein-based respiratory syncytial virus
(RSV) vaccine. RSV is the most common cause of lower respiratory illness in infants and young
children worldwide. It also plays significant role in respiratory illness in the elderly and in
immunocompromised patients. There is an urgent need and compelling reasons to develop RSV
vaccine. Past and current development efforts are mainly focused on F protein-based
recombinant vaccines and live attenuated vaccines. Despite major efforts for several decades, an
effective RSV vaccine remains elusive. RSV G protein is responsible for viral attachment to host
cells. However, only a single G-based vaccine has been studied in humans to date. Concern over
the high variability across RSV strains and limited knowledge in its surface structure and in vitro
function have contributed to its limited use as vaccine candidate. Recent advances in
understanding the roles of G in viral infection and in disease indicate that G should be recognized
as an important target for vaccine development. Preliminary studies indicate that our G protein-
based vaccine can provide protection against RSV infection in the animal models. Furthermore,
we have applied a rational design approach to generate candidates that have high potential to
induce broad protection. The main objective of this SBIR proposal is to rigorously evaluate the
candidates in two animal models. The proposed work will provide a critical foundation to move
the G protein-based RSV vaccine candidate toward clinical study.

## Key facts

- **NIH application ID:** 10224035
- **Project number:** 5R43AI149815-02
- **Recipient organization:** SCIOGEN, LLC
- **Principal Investigator:** SHENGQIANG LI
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $298,738
- **Award type:** 5
- **Project period:** 2020-08-01 → 2023-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10224035

## Citation

> US National Institutes of Health, RePORTER application 10224035, Optimization of G Protein-based RSV Vaccines (5R43AI149815-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10224035. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*